Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "R03DC"
<
Preisvergleich für Xolair 75 mg/0.5 ml
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Registr. Holder
Package Size
Composition
CP
%
SB
DC
IP
CI
Xolair 75 mg/0.5 ml
Novartis Pharma
Schweiz AG
Injection solution in prefilled syringe: Omalizumabum 75mg / 0.5ml
220.80
10 %
IP
CI
Xolair 75 mg/0.5 ml
Novartis Pharma
Schweiz AG
Injection solution in prefilled syringe: Omalizumabum 75mg / 0.5ml
220.80
+0%
10 %
IP
CI
Xolair 150 mg/1.0 ml
Novartis Pharma
Schweiz AG
Injection solution in prefilled syringe: Omalizumabum 150mg / 1ml
425.15
+92%
10 %
IP
CI
Xolair 150 mg/1.0 ml
Novartis Pharma
Schweiz AG
Injection solution in prefilled syringe: Omalizumabum 150mg / 1ml
425.15
+92%
10 %
IP
Xolair 300 mg/2 ml
Novartis Pharma
Schweiz AG
Injection solution in prefilled syringe: Omalizumabum 300mg / 2ml
833.90
+277%
10 %
For price comparison between Original and Generic please click onto the name of the drug all the way to the left!
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
